Atika Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Atika Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-157,000	Closed	-$16.9M	–	113
2021 Q4	$16.9M	Sell	157,000 -4,000	-2%	-$436K	1.19%	40
2021 Q3	$17.6M	Hold	161,000	–	–	1.05%	31
2021 Q2	$15.1M	Buy	161,000 +6,000	+4%	+$552K	1.19%	35
2021 Q1	$14.3M	Buy	+155,000	New	+$13.1M	1.24%	32
2020 Q4	–	Sell	-206,500	Closed	-$16M	–	155
2020 Q3	$16M	Buy	206,500 +33,500	+19%	+$2.3M	1.31%	25
2020 Q2	$9.62M	Buy	+173,000	New	+$7.4M	1.24%	30
2019 Q2	–	Sell	-155,000	Closed	-$4.1M	–	101
2019 Q1	$4.1M	Buy	+155,000	New	+$3.67M	0.83%	50
2016 Q4	–	Sell	-265,000	Closed	-$4.8M	–	79
2016 Q3	$4.8M	Sell	265,000 -168,000	-39%	-$3.28M	1.96%	16
2016 Q2	$7.13M	Buy	433,000 +193,000	+80%	+$3.12M	3.06%	7
2016 Q1	$3.98M	Buy	+240,000	New	+$4.2M	2.4%	17
2015 Q3	–	Sell	-129,650	Closed	-$4.5M	–	82
2015 Q2	$4.5M	Buy	+129,650	New	+$3.96M	2.03%	12

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atika Capital Management's HZNP Position: Q1 2022 in Review

Atika Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2022, closing a stake of 157,000 shares — an estimated $16.9M sold.

Atika Capital Management first reported a position in HZNP in Q2 2015 and held it in 11 quarters. The position peaked at $17.6M in Q3 2021. 620 funds tracked by Wall St. Rank hold HZNP as of Q1 2022.

Atika Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2022 after selling out during the quarter.
Atika Capital Management sold 157,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2022, an estimated $16.9M.
Atika Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 11 quarters.
Atika Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $17.6M in Q3 2021.
620 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2022.

Based on Atika Capital Management's 13F filing for Q1 2022, filed 13 May 2022.